Researchers at the Ovarian Cancer Research Centre in the University of Pennsylvania's Perelman School of Medicine have unveiled a new vaccine for treating ovarian cancer. Although rare (it is believed that only 1.38% of females will be afflicted), ovarian cancer is usually not diagnosed until stage 3 or 4. Lana Kandalaft, lead author in this study explains that this new treatment uses a personalized vaccine to instruct a patient's immune system to fight the tumor. "Each patient's tumor is unique like a fingerprint...we're trying to rewire the immune system to target the tumor."
Click here to read more about this study, presented on April 6th at the American Association for Cancer Research's annual meeting in Washington, D.C.
No comments:
Post a Comment